中高危前列腺癌放疗联合ADT后早期生化预测生存指标
单中心回顾性分析2566例中高危前列腺癌患者,其中1275例治疗前PSA<20 ng/mL且接受根治性放疗联合新辅助及同期ADT。多因素分析显示放疗后PSA≥0.09 ng/mL与生化复发、远处转移、前列腺癌特异性死亡及总生存显著恶化相关,而PSA较基线下降≥95%与生化复发和远处转移风险降低相关。
要点
- 放疗后早期PSA≥0.09 ng/mL提示生化复发、转移、特异性死亡及总生存均显著更差。
- 放疗后PSA较基线下降≥95%与生化复发和远处转移风险显著降低相关。
- 上述早期PSA指标可能帮助识别需要早期强化全身治疗的高危患者。
核心结论
- 放疗完成后早期PSA≥0.09 ng/mL与所有临床结局显著更差相关,早期PSA下降≥95%与生化复发和远处转移风险降低相关。
研究设计与样本
- 单中心回顾性综述纳入1990至2012年接受根治性放疗联合新辅助及同期ADT的2566例中高危前列腺癌患者。
- 其中1275例治疗前PSA<20 ng/mL且具备ADT启动后3个月内或放疗完成后3个月内PSA数据,中位随访7.6年。
- 采用Cox回归单因素及多因素分析评估治疗后PSA动力学与生化复发、远处转移、前列腺癌特异性死亡及总生存的关系。
主要发现
- 多因素分析显示放疗后PSA≥0.09 ng/mL与生化复发风险显著升高相关(HR 1.93;95%CI 1.45-2.57;p<0.001)。
- 放疗后PSA≥0.09 ng/mL与远处转移风险显著升高相关(HR 2.97;95%CI 2.01-4.39;p<0.001)。
- 放疗后PSA≥0.09 ng/mL与前列腺癌特异性死亡风险显著升高相关(HR 2.99;95%CI 1.73-5.15;p<0.001)。
- 放疗后PSA≥0.09 ng/mL与总生存显著恶化相关(HR 1.49;95%CI 1.18-1.86;p<0.001)。
- 放疗后PSA较基线下降≥95%与生化复发风险显著降低相关(MVA HR 0.58;95%CI 0.41-0.83;p=0.003)及远处转移风险显著降低相关(MVA HR 0.47;95%CI 0.30-0.76;p=0.002)。
关键数值与推荐
- 放疗完成后早期PSA阈值≥0.09 ng/mL用于识别预后显著更差的中高危前列腺癌患者。
- 放疗后PSA较基线下降≥95%作为与生化复发和远处转移风险降低相关的早期生化指标。
临床怎么用
- 对于接受根治性放疗联合ADT的中高危前列腺癌患者,可在放疗完成后早期检测PSA以进行风险分层。
- 放疗后PSA≥0.09 ng/mL或下降不足95%的患者可能需考虑早期强化全身治疗,但需进一步前瞻性验证。
局限性
- 本研究为单中心回顾性综述,存在选择偏倚可能。
- 仅纳入治疗前PSA<20 ng/mL且具备早期PSA数据的患者,结论外推受限。
- 早期PSA预测阈值及干预策略需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To identify early biochemical predictors of survival in intermediate- and high-risk prostate cancer patients with a pre-treatment PSA <20 ng/mL following definitive radiation therapy (RT) and androgen deprivation therapy (ADT). MATERIALS AND METHODS: A single-institution review of 2566 intermediate and high-risk prostate cancer patients treated with definitive RT and neoadjuvant and concurrent ADT from 1990 to 2012 was performed. The first prostate-specific antigen (PSA) value within three months of ADT initiation (post-ADT PSA) and the first PSA within three months after RT completion (post-RT PSA) were recorded. 1275 had baseline PSA <20 ng/mL and either post-ADT or post-RT PSA available. Median follow-up was 7.6 years. The relationship between post-treatment PSA kinetics and biochemical relapse (BR), distant metastasis (DM), prostate cancer specific death (PCSD) and overall survival (OS) was modeled using Cox regression univariate and multivariate analysis (MVA). RESULTS: MVA demonstrated a strong association between a post-RT PSA ≥0.09 ng/mL and a significantly higher risk of BR (HR: 1.93; 95% CI: 1.45-2.57; p < 0.001), DM (HR: 2.97; 95% CI: 2.01-4.39; p < 0.001), PCSD (HR: 2.99; 95% CI: 1.73-5.15; p < 0.001) and OS (HR: 1.49; 95% CI: 1.18-1.86; p < 0.001). Post-RT PSA reduction of ≥95% relative to the baseline PSA was associated with a significantly lower risk of BR (MVA HR: 0.58; 95% CI: 0.41-0.83; p = 0.003) and DM (MVA HR: 0.47; 95% CI: 0.30-0.76; p = 0.002). CONCLUSION: A PSA value ≥0.09 ng/mL early after RT completion is associated with significantly worse prognosis across all clinical outcomes, and an early PSA reduction of ≥95% is associated with reduced risk of BR and DM. These findings may identify patients who require early aggressive systemic management for high-risk disease.
引用
- Patel MA, Kollmeier M, McBride S, et al. Early biochemical predictors of survival in intermediate and high-risk prostate cancer treated with radiation and androgen deprivation therapy. Radiother Oncol. 2019. PMID: 31177042. doi:10.1016/j.radonc.2019.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。